摘要
目的探讨原发性高血压患者慢性压力负荷致左心室肥厚与基质金属蛋白酶3(MMP-3)、基质金属蛋白酶9(MMP-9)及金属蛋白酶组织抑制因子1(TIMP-1)血清水平的关系。方法收集原发性高血压患者140例,健康对照组132例,测定MMP-3、MMP-9和TIMP-1;行心脏彩超检查并计算左室重量指数(LVMI)。结果高血压组LVMI升高[(113.7±9.9)vs(88.3±10.4),P<0.001)],MMP-3、MMP-9和TIMP-1增高[(488.32±100.32 vs 314.59±99.78;340.56±43.21 vs 290.15±33.98;389.16±57.53 vs243.45±62.31;P<0.001)]。以LVMI为因变量的多元逐步回归分析显示,影响因素为年龄、SBP、MMP-3、MMP-9和TIMP-1(r2=0.78,P<0.001)。高血压组按LVMI分为高血压合并左心室肥厚组(A组)、高血压无左心室肥厚组(B组),A组SBP、MMP-3、MMP-9和TIMP-1升高[(178±31 vs 166±25);(490.14±99.13 vs 405.56±53.12);(340.56±43.21 vs 290.15±33.98);(393.45±47.69vs 301.58±39.57);P<0.05]。结论血清MMP-3、MMP-9和TIMP-1水平是高血压合并左心室肥厚的影响因素。
Objective To investigate the relationship of matrix metalloproteinases (MMP-3 and MMP-9) and the tissue inhibitor TIMP-1 with left ventricular hypertrophy (LVH) in patients with primary hypertension. Methods Totally 140 patients with primary hypertension and 132 healthy controls were included. Matrix metalloproteinase - 3 (MMP- 3 ) , matrix metalloproteinase - 9 (MMP- 9) and tissue inhibitor metalloproteinase - 1 ( TIMP- 1 ) were measured. All subjects were taken echecardiography examination, then left ventrieular mass index ( LVMI ) was calculated. Results MMP-3, MMP-9, TIMP- 1 (488.32±100.32 vs 314.59±99.78 ; 340.56±43.21 vs 290.15±33.98 ; 389.16±57.53 vs 243.45±62.31 ; P 〈0.001 ) and LVMI ( 113.7±9.9 vs 88.3±10.4, P 〈 0.001 ) in patients with primary hypertension were significandy higher than those in controls. In a mu/tiple stepwise regression analysis with LVMI as the variable, it was found that age, SBP, MMP-3, MMP-9 and TIMP- 1 were main determinants for LVMI (r^2 =0.78, P 〈 0.001 ). 3. Patients with primary hypertension were divided into two subgroups according to LVMI, i.e., hypertension with LVH (group A) and hypertension without LVH (group B). SBP, MMP-3, MMP-9 and TIMP-1 ( 178±31 vs 166±25 ;490.14±99.13 vs 405.56±53.12; 340.56±43.21 vs 290.15±33.98 ; 393.45±47.69 vs 301.58±39.57 ; P 〈 0.05 ) of group A were significantly higher than those of group B. Conclusion MMP-3, MMP-9 and TIMP- 1 are influencing factors for LVH in patients with primary hypertension.
出处
《中国医科大学学报》
CAS
CSCD
北大核心
2015年第6期485-488,共4页
Journal of China Medical University
基金
国家自然科学基金(81203002)